Severe Rapidly Progressive Interstitial Lung Disease Associated With Anti-MDA5
1 clinical trials · Condition
◉ Watch Severe Rapidly Progressive Interstitial Lung Disease Associated With Anti-MDA5
| Record | Firm | Date |
|---|---|---|
| Study of the Efficacy and Safety of a Bispecific Antibody, Teclistamab in Severe Rapidly Progressive Interstitial Lung Disease Associated With Anti-MDA5 (NCT07631208) | Assistance Publique - Hôpitaux de Paris | 2026-10-30 |
Track Severe Rapidly Progressive Interstitial Lung Disease Associated With Anti-MDA5 automatically
Every clearance here is in the API, with alerts when new ones post.